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Abstract 
Obesity is increasing, yet despite the necessity to maintain muscle mass and function with 
age, the effect of obesity on muscle protein turnover in older adults remains unknown. Eleven 
obese (BMI 31.9 ±1.1) and 15 healthy weight (HW; BMI 23.4 ±0.3) older men (55-75 years 
old) participated in a study that determined muscle protein synthesis (MPS) and leg protein 
breakdown (LPB) under post-absorptive (hypoinsulinaemic euglycaemic clamp) and post-
prandial (hyperinsulinemic hyperaminoacidaemic euglycaemic clamp) conditions. Obesity 
was associated with systemic inflammation, greater leg fat mass, and patterns of mRNA 
expression consistent with muscle deconditioning, whilst leg lean mass, strength and work 
done during maximal exercise were no different. Under post-absorptive conditions, MPS and 
LPB were equivalent between groups, while insulin and amino acid administration increased 
MPS in only HW subjects and was associated with lower leg glucose disposal (LGD, 63%) in 
obese. Blunting of MPS in the obese was offset by an apparent decline in LPB, which was 
absent in HW subjects. Lower post-prandial LGD in obese subjects and blunting of MPS 
responses to amino acids suggests obesity in older adults is associated with diminished 
muscle metabolic quality.  However this doesn’t appear to be associated with lower leg lean 
mass or strength.  
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Introduction 
Aging is strongly associated with a decline in muscle mass and strength (1). This has been in 
part attributed to the failure of protein nutrition to increase the rate of muscle protein 
synthesis (MPS) to that observed in the young (2), and the inability of hyperinsulinaemia to 
inhibit leg protein breakdown (LPB) in older people (3).  However, even after correcting for 
muscle mass loss, ageing has been allied with a decline in muscle strength and metabolic 
quality (4), signifying that physiological drivers other than muscle mass must contribute to 
weakness and diminished quality of muscle in older adults (5). 
 
It is widely reported that the prevalence of obesity is increasing in the developed world across 
all ages, including in older adults (6). Of concern, a longitudinal study in older adults showed 
that the temporal decline in lean mass and leg extension strength relative to leg mass (the 
latter used as an index of muscle quality) could be predicted by the degree of fat mass evident 
at time of recruitment (7). Furthermore, this relationship remained even when differences in 
physical activity levels were taken into account (8). The implication that older adults may be 
particularly at risk of accelerated muscle deterioration from obesity is supported by a cross-
sectional study involving 2,039 older men and women showing that the combination of low 
muscle strength and obesity was associated with poorer physical function than either in 
isolation (9). Crucially, whether the derangements in MPS and LPB described above for 
normal weight older adults (2; 3) are further exacerbated in obese older adults is unknown and 
forms the focus of the current study.  
 
Several reports provide credence that MPS and LPB may be negatively affected in obese 
individuals. When visceral fat mass is enlarged, plasma concentrations of TNFα, interleukin-6 
(IL-6), resistin and leptin appear increased (for a review see (10)). Furthermore, increased 
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plasma IL-6, c-reactive protein (CRP) and TNFα concentrations in older adults have been 
associated with the development of insulin resistance (11) and the decline of muscle mass and 
strength (12; 13). Moreover, in pre-clinical models characterised by systemic increases in 
TNFα and IL-6, cytokine mRNA expression in muscle is markedly elevated and processes 
involved in the promotion of protein synthesis inhibited in parallel to enhanced proteolysis 
(14; 15).  
 
Therefore, the aim of this study was to investigate if the response of MPS and LPB to 
experimentally induced post-absorptive and post-prandial conditions was different in obese 
older men compared to healthy weight older men, and if so, whether these responses could 
underlie any deficits in muscle mass and contractile function observed in obese older 
individuals.  
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Research Design and Methods 
 
Study participants 
Men between the ages of 55 and 75 were recruited and assigned to either a healthy weight 
(control) group if they were found to have a BMI < 26 and a serum CRP < 1.35 µg.ml-1 
(n=15) or obese group if a BMI > 29 and CRP > 1.35 µg.ml-1 (n=11). This benchmark was 
based on previous reports that serum CRP concentrations greater than 1.35 µg.ml-1 associate 
with increased levels of IL-6 and TNFα in obese individuals (16). All other individuals not 
meeting these criteria were excluded from participating. Subjects underwent a medical 
examination and were unable to participate if they had: type-II diabetes, previous diagnosis of 
cancer, unresolved hypertension, cardiovascular disease, on-going musculoskeletal 
complaints, frailty (underweight and self-reporting of exhaustion, weakness, slowness, and 
low physical activity levels; (17)) or any other chronic condition. Furthermore, subjects were 
not allowed to participate if they smoked, were trying to lose weight, were participating in 
regular organised sports, or taking anti-inflammatories, anti-depressants or statin medication. 
Characteristics of included subjects are presented in Table 1. Informed written-consent was 
obtained from volunteers and the study was approved by the University of Nottingham 
Medical School Ethics Committee and conducted in accordance with the Declaration of 
Helsinki. 
  
Muscle function protocol 
Subjects were instructed to refrain from alcohol and exercise for 48 h prior to each visit and 
attend the laboratory at 08:00 in a fasted state. On arrival, a whole-body dual-energy x-ray 
absorptiometry (DXA) scan was performed to assess lean and fat masses (Lunar Prodigy; GE 
Healthcare). Afterwards, a subset of volunteers (10 healthy weight and 8 obese subjects) 
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underwent isometric and isokinetic leg muscle function measurements as described in detail 
elsewhere (18).  
 
Metabolic study protocol 
A minimum of 72 h was allowed to elapse from the muscle function assessment visit before 
subjects returned to the laboratory to undergo detailed assessment of multiple whole-body and 
muscle metabolic parameters utilising an insulin-clamp protocol described previously (18). In 
short, a 240 min euglycaemic (4.5 mmol.l-1) insulin clamp began at t=0 with an insulin 
infusion rate of 0.6 mU.m-2.min-1 to maintain serum insulin concentrations similar to the 
fasting condition (~ 5mU.l-1) with octreotide (30 ng.kg-1.min-1) and glucagon (15 ng.kg-1.h-1) 
administered to block endogenous insulin production and maintain serum glucagon 
concentrations, respectively (Figure 1). At t=120 the insulin infusion rate was increased to 15 
mU.m-2.min-1 to achieve a serum insulin concentration equivalent to the post-prandial state 
(~40 mU.l-1). In parallel a mixed amino acid infusion (10 g.h-1; Glamin®, Fresenius Kabi, 
Germany) commenced which was maintained for the remaining 120 min of the study period. 
Throughout the entire 240 min period of the insulin clamp, a primed constant infusion of the 
stable-isotope labelled amino acids [1,2-13C2]-leucine and [ring-D5]-phenylalanine were 
administered (Figure 1). 
 
Muscle biopsies were obtained from the vastus lateralis by percutaneous needle biopsy at t=0, 
120 and 240 min. Arterialised-venous (a-v) blood samples were obtained at 5 min intervals 
for the determination of blood glucose (YSI2300 automated analyser, Yellow Springs, USA) 
and serum insulin concentrations by enzyme-linked immunosorbent assay (ELISA; DRG 
Diagnostics, Germany)); an additional sample taken at t=0 was used to determine circulating 
TNFα, IL-6, resistin, adiponectin and leptin concentrations by ELISA (R&D Systems Inc., 
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UK). Femoral venous blood samples taken in tandem with a-v blood samples at regular 
intervals were analysed for blood glucose concentrations to determine leg glucose disposal 
(LGD) between the period 210 to 240 min, reflecting steady-state under fed conditions. 
Arterialised-venous and femoral venous blood samples were obtained at t=0, 75, 90, 105, 120, 
195, 210, 225 and 240 min for the determination of [1,2-13C2]-leucine and [ring-D5]-
phenylalanine enrichment as previously described (19). Femoral artery blood flow was 
determined in the contralateral limb at these same time points using Doppler ultrasound 
(Aplio XV, Toshiba). Prior to the end of the 0.6 mU.m-2.min-1, and 15 mU.m-2.min-1 clamps, 
the respiratory exchange ratio (RER) was determined using a ventilated-hood indirect 
calorimetry system (GEM, GEM Nutrition Ltd, UK). 
 
Muscle protein synthesis 
Myofibrillar proteins were extracted from ~30 mg of muscle tissue as previously described 
(19). Following extraction, proteins were hydrolysed into their constituent amino acids via 
acid hydrolysis and purified using ion exchange chromatography (20). The resultant amino 
acids were derivatised as their N-acetyl-N-propyl esters and the incorporation of [1,2-13C2]-
leucine into protein determined by capillary gas chromatography combustion isotope ratio 
mass spectrometry (Delta-plus XL; Thermo Fisher Scientific, UK) according to established 
methods (20). The rate of MPS was determined by measuring the incorporation of [1,2-13C2]-
leucine in successive biopsies, with the labelling of blood α-KIC (alpha-ketoisocaproate) used 
as a surrogate measure for the immediate precursor for protein synthesis, leucyl-t-RNA (20). 
 
Leg protein turnover 
Whole-blood was used to determine labelling (atom % excess) and concentration of a-v and 
venous phenylalanine. Blood samples were precipitated with perchloric acid and the 
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supernatant neutralised prior to purification by cation exchange chromatography. The 
subsequent eluent was dried under nitrogen prior to derivatisation of amino acids to their tert-
butyldimethylsilyl derivatives using standard techniques (21). Concentrations and 
enrichments were determined by gas-chromatography mass-spectrometry (Trace DSQ, 
Thermo Scientific, UK) with the use of norleucine and d2-phenylalanine as internal standards. 
For each 120 min post-absorptive and post-prandial period, the values for enrichment and 
concentration were determined from the mean of 4 separately analysed samples, collected 
over the final 45 min. Leg protein synthesis (LPS) was calculated as the disappearance of 
phenylalanine into the leg and LPB as the arteriovenous dilution of [ring-D5]-phenylalanine as 
previously described (20). 
 
Gene expression analysis 
Total RNA was extracted from muscle biopsy specimens and cDNA synthesised using 
standard protocols (18). mRNA expression levels for 90 genes spanning carbohydrate 
metabolism, fat metabolism, insulin signalling and proteolysis were examined via the use of 
low-density microfluidic cards (Applied Biosystems, USA; see Table 2 for a comprehensive 
list of genes examined) and analysed on an Applied Biosystems 7900 Real-Time PCR system. 
Data was normalised to the geometric average of the housekeeping genes: alpha-actin, β2-
microglobulin, 18S and RNA polymerase 2A, with suitability of the housekeeping genes 
confirmed by the RealTime StatMiner software (Integromics, Spain). Gene expression was 
calculated via use of the 2-ΔΔCt method and significance determined by the linear modelling 
approach (LIMMA). The false discovery rate was assessed via the Benjamin and Hochberg 
method (22). 
 
Immunoblotting 
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Cytosolic proteins were extracted from 30 mg of muscle tissue and analysed by western blot 
using established methods (23). Membranes were incubated overnight at 4°C with a 
polyclonal antibody for either total or phosphorylation-specific forms of AKT1 (Thr308) or 
mTOR (Ser2448; Cell Signaling Technology Inc., USA) or as a loading control, beta-actin 
(Sigma, UK). Following washing in TBS-T, membranes were probed with a fluorescently-
labelled anti-mouse or anti-rabbit secondary antibody as appropriate (Dylight® conjugate, 
Cell Signaling Technology Inc., USA) and imaged on an electronic image acquisition system 
(Odyssey CLx, Licor Biosciences, USA). Band densities were determined using proprietary 
software supplied with the imaging system and normalised to the loading control. 
 
Statistics 
Statistical differences in subject characteristics, body composition, muscle functional data, 
plasma adipokine concentrations, and area under the curve data for serum insulin and glucose 
disposal rate (GDR) were determined using unpaired 2-tailed Student’s t-tests.  Differences in 
RER, femoral blood-flow, protein turnover measurements and western blot data were 
determined using a two-way ANOVA with repeated measures. When a significant interaction 
between main effects was observed, a Student’s t-test with Šidák correction was performed to 
locate differences. Correlation between changes in MPS with feeding and leg fat mass were 
assessed by linear regression analysis. Statistical analysis was performed using the Prism v6.0 
for Windows software (GraphPad Software Inc., USA). Data are reported as means ± SEM 
with significance accepted at the P < 0.05 level. 
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Results 
Adipokine expression 
Subjects were recruited based upon both their body mass index and basal serum CRP 
concentration. As a consequence, serum CRP concentration was greater in the obese versus 
the healthy weight individuals (P<0.001; Table 1). This selection strategy was effective at 
recruiting obese individuals with chronic low-grade inflammation relative to their healthy 
weight study counterparts, as evidenced by the greater plasma concentrations of leptin, 
resistin, TNFα and IL-6 in the obese individuals. Conversely, plasma concentrations of 
adiponectin were significantly lower in obese versus healthy weight subjects (Table 1) as 
anticipated (10). 
 
Body composition, muscle strength and muscle fatigue 
As expected, BMI was greater in the obese than that of the healthy weight participants (31.9 ± 
1.1 and 23.4 ± 0.3 kg.m-2, respectively; P<0.001). When examined in further detail using 
DXA, significantly greater fat masses were observed in the obese compared to the healthy 
weight subjects in all 5 body compartments interrogated (Figure 2A; P<0.001). Lean mass 
was also significantly greater in the obese individuals in the trunk (18% higher), android 
(26%) and gynoidal (14%) regions compared to the healthy weight subjects (Figure 2B). Lean 
tissue mass in the arms and legs of the lean and obese subjects was no different between the 
two subject groups. 
 
There was no significant difference in the isometric strength of the knee extensors between 
the healthy weight and obese individuals (34.3 ± 2.5 versus 33.9 ± 3.0 kg, respectively; Figure 
3A). Similarly, the volume of work performed during 30 maximal isokinetic knee extensions 
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was equivalent between subject groups (Figure 3B), as was a measure of fatigue calculated 
from changes in torque output over time (Figure 3C).  
 
Gene expression analysis 
mRNA expression levels for 90 genes spanning inflammation, carbohydrate and fat 
metabolism, insulin signalling and proteolysis were examined. Using a false discovery rate 
(FDR) < 0.10, 7 transcripts appeared differentially expressed in obese compared to lean 
volunteers (Table 2). Cytochrome c, peroxisome proliferator activated receptor-α, PPAR-γ 
coactivator 1-α and transcription factor A mitochondrial, all associated with either 
mitochondrial biogenesis or the control of mitochondrial oxidative phosphorylation, were 
expressed at lower levels in the muscle of obese individuals. Similarly, CD34, a marker of 
satellite cell quiescence, and the solute carrier organic anion transporter family member 1B1, 
involved in hepatic drug metabolism, were both lower in the obese. In contrast, the expression 
of myostatin, which has been shown to be a negative regulator of muscle growth, was greater 
in obese skeletal muscle (1.80-fold compared to controls; P<0.01). These changes are 
consistent with a general deconditioning of muscle in the obese subjects relative to healthy 
weight volunteers. Interestingly, in spite of the systemic low-grade inflammation seen in the 
obese volunteers, muscle mRNA levels for TNFα and IL-6 were not elevated. 
 
Carbohydrate metabolism 
Serum insulin concentrations under clamp conditions are presented in Figure 4A. The insulin 
infusions rates of 0.6 and 15 mU.m-2.min-1 produced steady-state serum insulin concentrations 
of 5.2 ± 1.2 and 69.7 ± 5.4 mU.L-1 in the lean, respectively, and 4.2 ± 0.3 and 78.7 ± 4.4 
mU.L-1 in the obese; there was no significant difference in either absolute serum insulin 
concentration or area under the curve during steady-state conditions between groups (Figure 
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4A). The 0.6 mU.m-2.min-1 insulin infusion resulted in negligible LGD in both subject groups 
(data not shown). In contrast, under steady-state conditions (210 to 240 min) the greater 
insulin infusion rate (15 mU.m-2.min-1) resulted in an increased rate of LGD in both sets of 
individuals, but was more marked in the lean (3.7 ± 0.4 g.min-1) than that of the obese (1.3 ± 
0.2 g.min-1) subjects over the 30 min period examined (Figure 4B; P<0.001). The RER was 
no different between subject groups in the simulated post-absorptive state (0.72 ± 0.02 and 
0.68 ± 0.01 in lean and obese subjects, respectively; Figure 4C). As expected, the simulated 
post-prandial state increased the RER in the healthy weight individuals (0.82 ± 0.03; 
P<0.001), but had no effect on obese volunteers where RER remained unchanged (0.71 ± 
0.01). 
 
Muscle protein turnover 
During the 0.6 mU.m-2.min-1 insulin infusion when mixed-amino acids were not being 
provided, the rates of MPS, LPS and LPB were equivalent between the healthy weight and 
obese volunteers (Figure 5A, 5C and 5D). Under these conditions, the rate of LPB exceeded 
LPS and as such, net leg phenylalanine balance was negative but equivalent between groups 
(Figure 5E). 
 
When serum insulin concentrations were increased and mixed-amino acids provided, arterial 
plasma phenylalanine concentrations doubled, from 60-80 µM to 130-150 µM in all 
volunteers (data not shown). Similarly, a doubling of the myofibrillar protein fractional 
synthetic rate was observed in healthy weight individuals (0.047 +/- 0.004 during fasted 
conditions versus 0.099 ± 0.011 %.h-1 under fed conditions; P<0.001), but no significant 
increase was observed in the obese volunteers (Figure 5A). When LPS was assessed by 
calculating phenylalanine disappearance into the leg (accepted to be a less sensitive approach 
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than muscle FSR), this difference between groups was still apparent but not significant 
(Figure 5C). While a main effect of hyperinsulinemia and hyperaminoacidemia to decrease 
LPB rates was observed, along with a trend towards an interaction between main effects 
(P=0.10; Figure 5D), proceeding with post-hoc tests revealed the decrease in LPB rates was 
confined to the obese (48.5 ± 9.5 fasted versus 29.9 ± 5.5 nmol.min-1.100 g leg mass-1 fed; 
P<0.01). Importantly, femoral blood flow, which impacts upon the determination of LPB 
rates, was equivalent between subject groups during both the fasted and fed clamps (Table 3). 
The culmination of these individual effects on LPS and LPB was that net leg phenylalanine 
balance was significantly enhanced in both subject groups (25.4 ± 6.7 versus 12.6 ± 5.1 
nmol.min-1.100 g leg mass-1 in the lean and obese, respectively; Figure 5E). Comparison of 
leg fat mass with the net change in muscle protein synthesis rates in the simulated post-
prandial state revealed a weak but significant (P=0.05) negative correlation between the two 
variables (Figure 5B). 
 
Anabolic signalling 
Under simulated post-absorptive conditions, total and phosphorylated protein levels of 
anabolic signalling intermediaries AKT and mTOR were of comparable magnitude between 
muscle samples of obese individuals and their healthy weight counterparts (Figure 5F). The 
simulated post-prandial state resulted in a significant and equivalent increase in AKT Thr308 
and mTOR Ser2448 phosphorylation levels in both groups. 
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Discussion 
Here we present novel evidence to suggest that obesity in non-frail, older men is not 
associated with deficits in lean mass, quadriceps strength or fatigability compared to healthy 
weight men of comparable age, despite systemic (but not muscle) inflammation being evident.  
Furthermore, we demonstrate for the first time that the ability of amino acids to increase MPS 
is blunted in obese, older men compared to their healthy weight counterparts, but that net leg 
phenylalanine balance is not affected due to a concomitant decrease in LPB in these 
individuals. In short, obesity appears to be associated with systemic inflammation, and altered 
MPS and LPB responses to increased nutrient delivery in older, non-frail men, but not 
reduced muscle mass or contractile function. Despite this, differences in whole body RER, 
LGD, and muscle mRNA changes consistent with a decline in overall muscle metabolic 
quality in obese older men were evident. These findings represent an important contribution 
to our understanding of the impact and interaction of systemic inflammation, ageing and 
obesity on muscle health.  
 
In the present study the lean masses of all body regions examined were found to be equivalent 
or greater in obese men compared with healthy weight counterparts of similar age. Moreover, 
isometric strength, and work output and fatigability during repeated maximal isokinetic 
contractions were identical between groups. This stands in contrast to the suggestion that 
obesity in old age accelerates muscle mass loss and functional decline (7; 8). Our lack of 
evidence to support the existence of increased sarcopenia or dynapenia in older, non-frail, 
obese men is however perhaps not surprising. In young individuals, obesity is typically 
associated with a 36% greater lean mass compared to lean counterparts of similar stature (24), 
thought due to the additional contractile work performed by the obese individual during 
locomotion and daily living. Furthermore, recent evidence has shown dynapenia to occur only 
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in a subset of obese older adults with prevalence of the condition largely equivalent between 
lean (36%) and obese (27%) individuals (9), suggesting that dynapenia occurs independently 
of obesity. However, we acknowledge that our observations need to be confirmed in a larger 
cohort using more sensitive measures of lean tissue mass than DXA, such as MRI or D3-
creatine dilution.  
 
While previous studies have attempted to detail the effects of obesity on MPS in young adults, 
a consensus has not emerged. For example, obesity has been associated with lower (25) and 
elevated (26) MPS in the post-absorptive state. Furthermore, whilst greater rates of whole-
body protein synthesis have been observed in obese younger volunteers in the fed state (27; 
28), the magnitude of increase in MPS from the post-absorptive to simulated fed state was 
comparable between non-obese and obese volunteers (25). In contrast, we report here that 
under post-absorptive conditions where muscle FSR is at its lowest, the rate at which muscle 
proteins were being synthesised was comparable between healthy weight and obese older 
men. More importantly, the stimulatory effect of increased amino acid provision during 
hyperinsulinaemia on MPS in the older obese adult was blunted when compared to their 
healthy weight counterparts. The exact basis for this “anabolic resistance” to amino acid 
provision is unclear, but is unlikely to be related to muscle inflammation given we could find 
no evidence of this despite clear systemic inflammation. One potential contributor is the 
increased intracellular accumulation of lipids within the muscles of obese individuals. A 
negative correlation between leg fat mass and the degree of stimulation of leg protein 
synthesis was observed (P<0.05), suggesting that the resistance to the anabolic actions of 
amino acids within the muscle tissue was as a direct result of the increased fat mass. 
Moreover, it has recently been shown that acute intravenous administration of a lipid 
emulsion (intralipid, 100ml/h) results in the blunting of MPS during a hyperinsulinaemic 
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euglycaemic clamp concomitant to amino acid feeding (29). However, whether this is a direct 
effect of lipid species on the mechanisms responsible for MPS, or is mediated via changes in 
insulin sensitivity cannot be deduced from the studies performed to date. 
 
The possible role of chronically reduced habitual physical activity levels in the anabolic 
resistance observed in the present study cannot be underestimated. Indeed, a recent study 
demonstrated that reducing daily step count by ~76% for 14 days in older individuals resulted 
in a 26% reduction in post-prandial rates of MPS and a 43% reduction in insulin sensitivity, 
but did not impact protein synthetic rates under post-absorptive conditions (30). Our own data 
demonstrate overt traits of muscle deconditioning were evident in the obese volunteers of the 
present study. For example, steady-state LGD and whole body carbohydrate oxidation rates 
were blunted in the obese volunteers, both of which are known to accompany inactivity (31).  
Furthermore, between group differences in muscle mRNA expression clearly indicates 
mitochondrial biogenesis and oxidative metabolism were dampened. Importantly, whilst daily 
physical activity levels were not measured in the present study, evidence suggests that even a 
1 hr period of daily vigorous exercise cannot compensate for the effects of inactivity on blood 
markers of poor musculoskeletal health if the remainder of the day is spent sitting (32). These 
findings support the assertion that greater muscle deconditioning had occurred in the obese 
individuals in the present study. 
 
Despite a failure of amino acids to stimulate MPS in the older obese men, the ability of 
insulin and amino acids to stimulate AKT and mTOR phosphorylation was unperturbed. A 
discord between AKT/mTOR signalling and MPS is not without precedent. Following 
stepwise increases in serum insulin concentration during conditions of hyperaminoacidemia in 
healthy, young volunteers, AKT phosphorylation paralleled the rise in insulin concentration 
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but was not matched by further increases in MPS and mTOR phosphorylation (20), 
suggesting AKT phosphorylation reflects insulin concentration rather than any measure of 
protein synthesis. Likewise, with its suggested role as an amino acid sensor, mTOR 
phosphorylation may reflect extracellular amino acid availability rather than commitment of 
the muscle cell to enhance MPS. As such, our results show clearly that the failure of amino 
acids to stimulate MPS in the older obese men is not due to an inability to phosphorylate AKT 
and mTOR. 
 
Whole-body protein breakdown has been found to be inhibited less in the fed state in obese 
versus non-obese younger subjects (25).  However, given muscle is reported to account for 
only 25% of whole-body proteolysis in the basal state (33), the implications of these findings 
remain unclear.  Despite obese individuals being in a heightened systemic-inflammatory state 
in the present study, this did not translate into increased LPB under post-absorptive 
conditions. Indeed, our results suggest that the rate of LPB in the post-prandial state was 
lower in obese than healthy weight volunteers. Therefore, the inability of amino acids to 
stimulate MPS in the obese appeared largely offset by a concomitant decline in the rate of 
LPB, culminating in the magnitude of change in net phenylalanine balance between the post-
absorptive and post-prandial state being equivalent between lean and obese subjects. This 
represents one potential mechanism for the equivalent leg lean mass seen between groups, 
although the consequence of assessing volunteers under acute conditions in the rested state is 
that the contribution of habitual physical activity levels and dietary behaviour on chronic 
muscle protein turnover and thereby muscle mass, remains unknown. 
 
Obesity in older men is aligned with systemic, but not muscle, inflammation. We found no 
evidence that obese, non-frail, older men are at increased risk of accelerated muscle mass loss 
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or impaired contractile function (strength and fatigability) compared to their healthy weight 
counterparts. However, our results highlight the negative effect that obesity has on the 
metabolic quality of skeletal muscle in older adults. The exact role that inactivity plays in the 
decline in muscle metabolic health in the older obese adult remains unclear, but it could prove 
the central causative feature and should be the focus of future work.  
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Table 1: Subject characteristics 
 Lean (n=15) Obese (n=11) 
Age (yrs) 66.7 ± 1.1 66.4 ± 1.8 
Height (cm) 176 ± 2 175 ± 2 
Weight (kg) 72.8 ± 2.0 97.7 ± 3.6 *** 
BMI (kg.m-2) 23.4 ± 0.3 31.9 ± 1.1 *** 
Body fat mass (%) 22.7 ± 1.5 36.4 ± 1.0 *** 
Diastolic blood pressure (mmHg) 83 ± 1 84 ± 2 
Systolic blood pressure (mmHg) 131 ± 2 141 ± 2 ** 
Total blood cholesterol concentration 
(mmol.l-1) 
5.8 ± 0.3 (n=12) 6.5 ± 0.4 (n=8) 
Fasting blood glucose concentration 
(mmol.l-1) 
4.68 ± 0.15 4.81 ± 0.19 
Fasting serum insulin concentration 
(mU.l-1) 
5.2 ± 0.2 10.1 ± 1.8 ** 
Serum c-reactive protein concentration 
(µg.ml-1) 
0.69 ± 0.09 4.20 ± 0.83 *** 
Plasma adiponectin concentration 
(ng.ml-1) 
11.6 ± 1.1 6.7 ± 1.2 ** 
Plasma IL-6 concentration (pg.ml-1) 0.84 ± 0.16 1.98 ± 0.29 ** 
Plasma leptin concentration (ng.ml-1) 2.35 ± 0.31 9.58 ± 1.15 *** 
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Plasma resistin concentration (ng.ml-1) 4.93 ± 0.34 6.43 ± 0.49 * 
Plasma TNFα concentration (pg.ml-1) 1.21 ± 0.20 2.28 ± 0.47 * 
Medications 
Aspirin 75 mg daily 
(n=1) 
Atenolol 50 mg daily 
(n=1); aspirin 75 mg daily 
(n=1); lisinopril 40 mg 
daily; germaloids cream as 
required (n=1). 
   
Values represent means ± SEM. *** P<0.001, ** P<0.01, * P<0.05 significantly different 
from lean subjects. 
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Table 2: Changes in mRNA levels of several transcripts associated with metabolism or 
muscle growth in skeletal muscle of obese older men.  
Pathway Gene 
Gene 
code 
Probe 
identifier 
Fold 
change 
P-
value 
FDR 
Apoptosis Apoptotic peptidase 
activating factor 1 
APAF1 Hs00559441 1.04 0.582 0.856 
B-cell 
CLL/lymphoma 2 
BCL2 Hs00608023 1.19 0.055 0.291 
Caspase 8 CASP8 Hs01018151 1.04 0.727 0.894 
Caspase 9 CASP9 Hs00154261 0.97 0.637 0.861 
Diablo, IAP-binding 
mitochondrial protein 
DIABL
O 
Hs00219876 0.98 0.693 0.890 
Autophagy BCL2/adenovirus 
E1B 19kda 
interacting protein 3 
BNIP3 Hs00969291 1.07 0.269 0.676 
Dynamin 1-like DNM1L Hs00247147 0.91 0.027 0.223 
GABA(A) receptor-
associated protein 
GABAR
AP 
Hs00925899 0.88 0.028 0.223 
Calcium 
release 
Ryanodine receptor 1 RYR1 Hs00166991 1.00 0.988 0.988 
Ryanodine receptor 3 RYR3 Hs00168821 0.65 0.033 0.223 
Carbohydr Creatine kinase CKM Hs00176490 0.21 0.411 0.839 
27	  
	  
ate 
metabolis
m 
Lactate 
dehydrogenase B 
LDHB Hs00929956 0.91 0.919 0.985 
NADH 
dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 
5 
NDUFA
5 
Hs00606273 0.83 0.008 0.102 
Pyruvate 
dehydrogenase 
kinase, isozyme 4 
PDK4 Hs00176875 1.10 0.786 0.932 
Solute carrier family 
22 (organic 
cation/ergothioneine 
transporter), 
member 4 
 
GLUT4 Hs00268200 0.89 0.814 0.953  
Inflammati
on 
Interleukin 6 IL-6 Hs00985639 0.67 0.405 0.839 
Metallothionein 1A MT1A Hs00831826 0.84 0.533 0.856 
Tumor necrosis 
factor α 
TNFα Hs99999043 0.80 0.423 0.839 
Insulin 
signalling 
Eukaryotic 
translation initiation 
factor 2B, subunit 2 
EIF2B2 Hs00204540 0.84 0.015 0.162 
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beta 
Mitogen-activated 
protein kinase 3 
MAPK3 Hs00385075 0.90 0.06 0.306 
Mitogen-activated 
protein kinase kinase 
1 
MAP2K
1 
Hs00605615 1.04 0.568 0.856 
Phosphoinositide-3-
kinase, regulatory 
subunit 1 (alpha) 
PIK3R1 Hs00933163 0.59 0.148 0.489 
Protein kinase, AMP-
activated, alpha 1 
catalytic subunit 
PRKAA
1 
Hs01562308 0.94 0.141 0.482 
Ras homolog family 
member Q 
RHOQ Hs00817629 1.07 0.183 0.550 
RAS p21 protein 
activator (gtpase 
activating protein) 1 
RASA1 Hs00243115 0.98 0.710 0.890 
Ras-related GTP 
binding A 
RRAGA Hs00538975 1.01 0.779 0.932 
V-akt murine 
thymoma viral 
oncogene homolog 2 
 
AKT2 Hs01086102 0.95 0.275 0.676 
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Lipid 
metabolis
m 
Carnitine 
palmitoyltransferase 
1B 
CPT1B Hs00993896 0.78 0.080 0.322 
Carnitine transporter 
OCTN2 
SLC22A
5 
Hs00161895 0.69 0.164 0.524 
Farnesyl diphosphate 
synthase 
FDPS Hs00266635 0.95 0.666 0.876 
Fatty acid binding 
protein 3 
FABP3 Hs00269758 0.79 0.107 0.411 
Fatty acid synthase FASN Hs00188012 1.12 0.489 0.856 
 
Fatty acid 
translocase/CD36 
CD36 Hs00169627 0.93 0.413 0.839 
Heat shock 70kda 
protein 5 
HSPA5 Hs99999174 1.04 0.575 0.856 
NADH 
dehydrogenase  
(ubiquinone) Fe-S 
protein4 
NDUFS
4 
Hs00942568 0.87 0.068 0.322 
Protein kinase C, 
alpha, 
PRKCA Hs00925195 0.94 0.555 0.856 
Protein kinase C, PRKCE Hs00178455 1.02 0.859 0.963 
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epsilon 
Protein kinase C, iota PRKCI Hs00702254 1.06 0.548 0.856 
Protein kinase C, 
theta 
PRKCQ Hs00989970 0.97 0.630 0.861 
Stearoyl-coa 
desaturase 1 
SCD Hs01682761 1.30 0.550 0.856 
Myogenesi
s 
 
CD34 molecule CD34 Hs00990732 0.79 0.004 0.068 
m-cadherin 15 CDH15 Hs00170504 1.09 0.292 0.700 
Met proto-oncogene MET Hs01565584 1.13 0.191 0.556 
Myogenic factor 5 MYF5 Hs00271574 1.21 0.029 0.223 
Ras homolog 
enriched in brain 
RHEB Hs00950800 1.00 0.971 0.985 
Ras homolog family 
member A 
RHOA Hs00236938 1.06 0.247 0.659 
Ras homolog family 
member B 
RHOB Hs00269660 1.09 0.367 0.820 
Rho-associated, 
coiled-coil containing 
protein kinase 1 
ROCK1 Hs00178463 1.00 0.949 0.985 
V-Ha-ras Harvey rat 
sarcoma viral 
oncogene homolog 
HRAS Hs00610483 0.99 0.863 0.963 
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Organic 
anion 
transporter 
Solute carrier 
organic anion 
transporter family, 
member 1B1 
SLCO1
B1 
Hs00272374 0.05 0.004 0.068 
Oxidative 
phosphoryl
ation / 
Electronic 
Transport 
Chain 
Coenzyme Q10 
homolog B 
COQ10
B 
Hs00257861 1.24 0.497 0.856 
COX-I, Cytochrome 
C oxidase I 
MT-CO1 Hs02596864 0.81 0.031 0.223 
COXII, Cytochrome 
C Oxidase2 
MT-CO2 Hs00153133 0.71 0.472 0.856 
Cytochrome c CYCS Hs01588974 0.70 0.000 0.014 
Cytochrome c 
oxidase subunit viia 
polypeptide 1 
COX7A
1 
Hs00156989 0.85 0.074 0.322 
Succinate 
dehydrogenase 
complex II 
SDHA Hs00188166 0.89 0.077 0.322 
Ubiquinol-
cytochrome c 
reductase, complex 
III 
UQCRQ Hs00416927 0.85 0.055 0.291 
Proteolysis Calpain 1 CAPN1 Hs00559804 1.03 0.513 0.856 
Calpain 2 CAPN2 Hs00965092 0.96 0.477 0.856 
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Calpain 3, (p94) CAPN3 Hs00544975 1.03 0.593 0.856 
Calpastatin CAST Hs00156280 1.01 0.943 0.985 
Cathepsin L1 CTSL1 Hs00377632 0.92 0.201 0.568 
F-box protein 32 MAFbx Hs01041408 1.02 0.840 0.963 
Matrix 
metallopeptidase 2 
MMP2 Hs01548727 1.06 0.595 0.856 
Proteasome subunit, 
beta 1 
PSMB1 Hs00427357 1.04 0.666 0.876 
Proteasome subunit, 
beta 2 
PSMB2 Hs01002946 1.03 0.604 0.856 
Proteasome subunit, 
beta 5 
PSMB5 Hs00605652 1.02 0.714 0.890 
Tripartite motif 
containing 63, E3 
ubiquitin protein 
ligase 
MuRF1 Hs00261590 0.85 0.310 0.726 
Ubiquitin B UBB Hs00430290 1.00 0.975 0.985 
Ubiquitin C UBC Hs00824723 1.06 0.548 0.856 
Ubiquitin specific 
peptidase 19 
USP19 Hs00324123 1.06 0.226 0.619 
Regulator 
of cell 
Myostatin MSTN Hs00976237 1.8 0.004 0.068 
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growth 
Transcripti
on factor 
Activating 
transcription factor 3 
ATF3 Hs00231069 0.89 0.606 0.856 
Forkhead box O1 FOXO1 Hs00231106 1.01 0.959 0.985 
Forkhead box O3 FOXO3 Hs00818121 0.96 0.704 0.890 
Inhibitor of kappa 
light polypeptide 
gene enhancer in B-
cells, kinase beta 
IKBKB Hs00233287 0.95 0.532 0.856 
Jun proto-oncogene JUN Hs00277190 1.08 0.380 0.829 
Myocyte enhancer 
factor 2C 
MEF2C Hs00231149 1.00 0.972 0.985 
Myogenic 
differentiation 1 
MYOD1 Hs00159528 1.01 0.924 0.985 
Myogenin (myogenic 
factor 4) 
MYOG Hs00231167 1.19 0.046 0.286 
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 1 
NFKB1 Hs00765730 1.12 0.048 0.286 
Nuclear factor of 
kappa light 
NFKB2 Hs00174517 1.06 0.519 0.856 
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polypeptide gene 
enhancer in B-cells 2 
(p49/p100) 
Peroxisome 
proliferator-
activated receptor 
alpha 
PPARA Hs00231882 0.77 0.002 0.068 
Peroxisome 
proliferator-activated 
receptor delta 
PPARD Hs00602622 0.94 0.273 0.676 
Peroxisome 
proliferator-activated 
receptor gamma 
PPARG Hs01115513 0.85 0.081 0.322 
Peroxisome 
proliferator-
activated receptor 
gamma, 
coactivator 1 alpha 
PPARG
C1A 
Hs01016724 0.67 0.002 0.068 
 
Sterol regulatory 
element binding 
transcription factor 1 
SREBF1 Hs01088691 1.11 0.428 0.839 
Sterol regulatory 
element binding 
SREBF2 Hs01081778 1.02 0.785 0.932 
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transcription factor 2 
Transcription factor 
A, mitochondrial 
TFAM Hs01082775 0.88 0.006 0.088 
V-rel 
reticuloendotheliosis 
viral oncogene 
homolog A 
RELA Hs00153294 1.00 0.96 0.985 
 
Seven genes, highlighted in bold and underlined, satisfied the criteria FDR < 0.1 and were 
considered differentially expressed. Fold changes expressed relative to lean subjects.   
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Table 3: Femoral blood flow in healthy weight and obese volunteers as assessed by 
Doppler ultrasound at baseline and in the last 30 minutes of the fasted and fed clamps. 
 Lean (n=15) Obese (n=11) 
Baseline 385 ± 34 358 ± 30 
Fasted state insulin clamp 
(insulin 0.6 mU.m-2.min-1) 
512 ± 48 472 ± 56 
Fed state insulin clamp 
(insulin 15 mU.m-2.min-1 plus 
mixed amino acid infusion (10 
g.h-1) 
529 ± 45 450 ± 51 
 
Results expressed in ml/min and values represent mean ± SEM. A significant main effect of 
insulin treatment was observed (P<0.001). No significant main effect of BMI stratification 
was observed or an interaction between main effects. 
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Figure 1: Study protocol for the measurement of muscle protein synthesis and leg 
protein breakdown in the post-absorptive (0-120 min) and post-prandial (120-240 min) 
states. For clarity, A-V blood sampling is not indicated, but occurred at regular intervals 
throughout the study period. 
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Figure 2: Regional fat and lean masses in healthy weight and obese older men. Mean 
values ± SEM for fat mass (A) and lean mass (B) in lean and obese volunteers separated by 
anatomical region. C) Diagrammatic representation of the approximate trunk, android and 
gynoid regions determined by the DXA imaging software. *** P<0.001, ** P<0.01, 
significantly different from healthy weight individuals. 
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Figure 3: Isometric strength, total work output and fatigue index during 30 maximal 
isokinetic knee extensions (at 90°.s-1) in older healthy weight and obese men. Values 
represent mean ± SEM for isometric strength (A), work done (B) and fatigue index ((peak 
torque-minimum torque)/peak torque) (C). No significant differences were observed between 
lean and obese individuals for any of the three parameters examined. 
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Figure 4: Serum insulin concentration, leg glucose uptake and respiratory exchange 
ratio in fasted and fed state conditions in older healthy weight and obese men. Mean ± 
SEM concentration of serum insulin (A) and leg glucose disposal (B) in response to a 
hypoaminoacidemia/hypoinsulinemic (0-120 min; insulin data only shown) clamp and a 
hyperaminoacidemia/hyperinsulinemic (120-240 min) euglycaemic clamp. Enclosed bar chart 
denotes area under the insulin curve (A) or leg glucose disposal rate (B) calculated over the 
last 30 min of the hyperaminoacidaemic hyperinsulinaemic clamp (shaded region on graphs A 
and B). Mean values ± SEM for respiratory exchange ratio (C) in healthy weight and obese 
older adults in both the post-absorptive and post-prandial states. Where relevant, P-values as 
determined by 2-way ANOVA for each main effect and interaction between main effects 
displayed alongside corresponding graph. NS: not significant; *** P<0.001, ** P<0.01 
significantly different from healthy weight individuals; ††† P<0.001, significantly different 
from fasted clamp conditions. 
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Figure 5: Muscle protein turnover and associated signalling in post-absorptive and post-
prandial states in older healthy weight and obese men. Myofibrillar fractional synthetic 
rate (A) assessed in healthy weight and obese individuals following simulated fasted or fed 
conditions. A negative correlation was observed between leg fat mass and change in muscle 
protein synthesis with feeding (B) which was significant by linear regression analysis 
(P=0.05). Leg protein synthesis rate (C), leg protein breakdown rate (D) and phenylalanine 
balance across the leg (E). To delineate the processes underpinning the observed changes in 
MPS, total protein levels and main phosphorylated forms of AKT and mTOR were 
determined by western blot (F). Bars represent mean values ± SEM. Where relevant, P-values 
as determined by 2-way ANOVA for each main effect and interaction between main effects 
displayed alongside corresponding graph. NS: not significant; ** P<0.01, significantly 
different from lean individuals; ††† P<0.001, †† P<0.01, significantly different from fasted 
clamp conditions. 
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